Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes —...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Brown, Christine E., Alizadeh, Darya, Starr, Renate, Weng, Lihong, Wagner, Jamie R., Naranjo, Araceli, Ostberg, Julie R., Blanchard, M. Suzette, Kilpatrick, Julie, Simpson, Jennifer, Kurien, Anita, Priceman, Saul J., Wang, Xiuli, Harshbarger, Todd L., D’Apuzzo, Massimo, Ressler, Julie A., Jensen, Michael C., Barish, Michael E., Chen, Mike, Portnow, Jana, Forman, Stephen J., Badie, Behnam
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5390684/
https://ncbi.nlm.nih.gov/pubmed/28029927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1610497
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares